Diagnosis and treatment of malignant pleural effusion: A systematic literature review and new approaches

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 4, 2010, Pages 420-423

  Lombardi, Giuseppe ^a   Zustovich, Fable ^a   Nicoletto, Maria Ornella ^a   Donach, Martin ^a   Artioli, Grazia ^a   Pastorelli, Davide ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Effusion; Pleura; Pleurodesis; Talc; Tumor

Indexed keywords

BLEOMYCIN; CISPLATIN; DOXYCYCLINE; ERYTHROMYCIN; MITOXANTRONE; PACLITAXEL; TALC; TETRACYCLINE;

ACUTE RESPIRATORY FAILURE; ATELECTASIS; CATHETER; CLINICAL EXAMINATION; CLINICAL TRIAL; COMORBIDITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DYSPNEA; GENETICS; HUMAN; HYPOXEMIA; IMMUNOHISTOCHEMISTRY; LIFE EXPECTANCY; MEDICAL LITERATURE; PALLIATIVE THERAPY; PATIENT SAFETY; PLEURA BIOPSY; PLEURA EFFUSION; PLEURA FLUID; PLEURODESIS; PNEUMONIA; REVIEW; SHUNTING; SURVIVAL; SYSTEMATIC REVIEW; THORACOCENTESIS; BIOPSY; INDWELLING CATHETER; LUNG; LUNG COMPLIANCE; MORTALITY; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PLEURA;

BIOPSY; CATHETERS, INDWELLING; HUMANS; LUNG; LUNG COMPLIANCE; NEOPLASMS; PALLIATIVE CARE; PLEURA; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS; SURVIVAL ANALYSIS;

EID: 77956632064     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181aacbbf     Document Type: Review

References (68)

1. Antunes G, Neville E. Management of malignant pleural effusions. Thorax. 2000;55:981-983.
2. Bennett R, Maskell N. Management of malignant pleural effusions. Curr Opin Pulm Med. 2005;11:296-300.
3. Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999;85:178-187.
4. Sahn SA. Malignant pleural effusion. In: Fishman AP, ed. Pulmonary Disease and Disorder. New York, NY: Mc-Graw-Hill; 1988:2159-2169.
5. Leung AN, Muller NL, Miller RR. CT in differential diagnosis of diffuse pleural disease. Am J Roentgenol. 1990;154:487-492.
6. Falaschi F, Battolla L, Mascalchi M, et al. Usefulness of MR signal intensity in distinguishing benign from malignant pleural disease. Am J Roentgenol. 1996;166:963-968. (Pubitemid 26102085)
7. Duysinx BC, Larock MP, Nguyen D, et al. 18F-FDG PET imaging in assessing exudative pleural effusions. Nucl Med Commun. 2006;27:971-976.
8. Toaff JS, Metser U, Gottfried M, et al. Differentiation between malignant and benign pleural effusion in patients with extra-pleural primary malignancies: Assessment with positron emission tomography-computed tomography. Invest Radiol. 2005;40:204-209.
9. Yam LT. Diagnostic significance of lymphocytes in pleural effusions. Ann Intern Med. 1967;66:972-982.
10. Matthai SM, Kini U. Diagnostic value of eosinophils in pleural effusion: A prospective study of 26 cases. Diagn Cytopathol. 2003;28:96-99.
11. Rodriguez-Panadero F, Lopez Mejias J. Low glucose and pH levels in malignant pleural effusions. Diagnostic significance and prognostic value in respect to pleurodesis. Am Rev Respir Dis. 1989;139:663-667.
12. Gaspar MJ, De Miguel J, Garcia Diaz JD, et al. Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions. Anticancer Res. 2008;28:2947-2952.
13. Duysinx BC, Corhay JL, Hubin L, et al. Diagnostic value of interleukine-6, transforming growth factor-beta 1 and vascular endothelial growth factor in malignant pleural effusions. Respir Med. 2008;102:1708-1714.
14. Hsu C. Cytologic detection of malignancy in pleural effusion: A review of 5255 samples from 3811 patients. Diagn Cytopathol. 1987;3:8-12.
15. Johnston WW. The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer. 1985; 56:905-909.
16. Starr RL, Sherman ME. The value of multiple preparations in the diagnosis of malignant pleural effusions. A cost-benefit analysis. Acta Cytol. 1991;35: 533-537.
17. Pu RT, Giordano TJ, Michael CW. Utility of cytology microarray constructed from effusion cell blocks for immunomarker validation. Cancer. 2008;114:300-306.
18. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353:1591-1603.
19. Whitaker D. The cytology of malignant mesothelioma. Cytopathology. 2000; 11:139-151.
20. Prakash UB, Reiman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: Analysis of 414 cases. Mayo Clin Proc. 1985;60:158-164.
21. Rahman NM, Gleeson FV. Image-guided pleural biopsy. Curr Opin Pulm Med. 2008;14:331-336.
22. Lee YC, Light RW. Management of malignant pleural effusions. Respirology. 2004;9:148-156.
23. Antunes G, Neville E, Duffy J, et al. BTS guidelines for the management of malignant pleural effusions. Thorax. 2003;58(suppl 2):ii29 -ii38.
24. Antony VB, Nasreen N, Mohammed KA, et al. Talc pleurodesis: Basic fibroblast growth factor mediates pleural fibrosis. Chest. 2004;126:1522-1528.
25. Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc. 2008;83:235-250.
26. Debeljak A, Kecelj P, Triller N, et al. Talc pleurodesis: Comparison of talc slurry instillation with thoracoscopic talc insufflation for malignant pleural effusions. J BUON. 2006;11:463-467.
27. Margaritora S, Cesario A, Vita ML, et al. Single versus multiple access video-assisted thoracic surgery in the treatment of malignant pleural effusion. Eur J Cardiothorac Surg. 2007;32:397; author reply 97-98.
28. Stefani A, Natali P, Casali C, et al. Talc poudrage versus talc slurry in the treatment of malignant pleural effusion. A prospective comparative study. Eur J Cardiothorac Surg. 2006;30:827-832.
29. Tan C, Sedrakyan A, Browne J, et al. The evidence on the effectiveness of management for malignant pleural effusion: A systematic review. Eur J Cardiothorac Surg. 2006;29:829-838.
30. Haddad FJ, Younes RN, Gross JL, et al. Pleurodesis in patients with malignant pleural effusions: Talc slurry or bleomycin? Results of a prospective randomized trial. World J Surg. 2004;28:749 -53; discussion 53-54.
31. Kilic D, Akay H, Kavukcu S, et al. Management of recurrent malignant pleural effusion with chemical pleurodesis. Surg Today. 2005;35:634-638.
32. Ong KC, Indumathi V, Raghuram J, et al. A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant pleural effusions. Respirology. 2000;5:99-103.
33. Patz EF Jr, McAdams HP, Erasmus JJ, et al. Sclerotherapy for malignant pleural effusions: A prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage. Chest. 1998;113:1305-1311.
34. Sartori S, Tassinari D, Ceccotti P, et al. Prospective randomized trial of intrapleural bleomycin versus interferon alfa-2b via ultrasound-guided smallbore chest tube in the palliative treatment of malignant pleural effusions. J Clin Oncol. 2004;22:1228-1233.
35. Emad A, Rezaian GR. Treatment of malignant pleural effusions with a combination of bleomycin and tetracycline. A comparison of bleomycin or tetracycline alone versus a combination of bleomycin and tetracycline. Cancer. 1996;78:2498-2501.
36. Freitas S, Jones J, Cordeiro C, et al. Pleurodesis with tetracyclin or with talc-Variables in terms of effectiveness. Rev Port Pneumol. 2005;11: 13-14.
37. Martinez-Moragon E, Aparicio J, Rogado MC, et al. Pleurodesis in malignant pleural effusions: A randomized study of tetracycline versus bleomycin. Eur Respir J. 1997;10:2380-2383.
38. Villanueva AG, Gray AW Jr, Shahian DM, et al. Efficacy of short term versus long term tube thoracostomy drainage before tetracycline pleurodesis in the treatment of malignant pleural effusions. Thorax. 1994;49:23-25.
39. Hoffer FA, Hancock ML, Hinds PS, et al. Pleurodesis for effusions in pediatric oncology patients at end of life. Pediatr Radiol. 2007;37:269-273.
40. Kuzdzal J, Sladek K, Wasowski D, et al. Talc powder vs doxycycline in the control of malignant pleural effusion: A prospective, randomized trial. Med Sci Monit 2003;9:PI54 -PI59.
41. Porcel JM, Salud A, Nabal M, et al. Rapid pleurodesis with doxycycline through a small-bore catheter for the treatment of metastatic malignant effusions. Support Care Cancer. 2006;14:475-478.
42. Dasmahapatra KS, Citrin P, Hill GJ, et al. A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous-cell cancer of the head and neck. J Clin Oncol. 1985;3:1486-1489.
43. Seto T, Ushijima S, Yamamoto H, et al. Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer: A multi-institutional phase II trial. Br J Cancer. 2006;95:717-721.
44. Shoji T, Tanaka F, Yanagihara K, et al. Phase II study of repeated intrapleural chemotherapy using implantable access system for management of malignant pleural effusion. Chest. 2002;121:821-824.
45. Balassoulis G, Sichletidis L, Spyratos D, et al. Efficacy and safety of erythromycin as sclerosing agent in patients with recurrent malignant pleural effusion. Am J Clin Oncol. 2008;31:384-389.
46. Miller Q, Meschter C, Neumaster T, et al. Comparison of pleurodesis by erythromycin, talc, doxycycline, and diazepam in a rabbit model. J Surg Educ. 2007;64:41-45.
47. Tang X, Cheng D. The value of erythromycin pleurodesis in the treatment of malignant pleural effusions. Hua Xi Yi Ke Da Xue Xue Bao. 1997;28:437-439.
48. Barbetakis N, Antoniadis T, Tsilikas C. Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer. World J Surg Oncol. 2004;2:16.
49. Barbetakis N, Vassiliadis M, Kaplanis K, et al. Mitoxantrone pleurodesis to palliate malignant pleural effusion secondary to ovarian cancer. BMC Palliat Care. 2004;3:4.
50. Schmidt M, Schaarschmidt G, Chemaissani A. Pleurodesis in malignant pleural effusion: Bleomycin vs. mitoxantrone. Pneumologie. 1997;51:367-372.
51. Ohta Y, Shimizu Y, Matsumoto I, et al. Management of malignant pleural effusion by multimodality treatment including the use of paclitaxel administered by 24-hour intrathoracic infusion for patients with carcinomatous pleuritis. J Exp Clin Cancer Res. 2006;25:15-19.
52. Perng RP, Chen YM, Wu MF, et al. Phase II trial of intrapleural paclitaxel injection for non-small-cell lung cancer patients with malignant pleural effusions. Respir Med. 1998;92:473-479.
53. Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev. 2004:CD002916.
54. Dresler CM, Olak J, Herndon JE II, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005;127:909-915.
55. Griffo S, Musumeci A, De Luca G, et al. Talc-induced interstitial pneumonitis with respiratory failure. Anaesth Intensive Care. 2009;37:127-129.
56. Chen H, Brahmer J. Management of malignant pleural effusion. Curr Oncol Rep. 2008;10:287-293.
57. Janssen JP, Collier G, Astoul P, et al. Safety of pleurodesis with talc poudrage in malignant pleural effusion: A prospective cohort study. Lancet. 2007;369: 1535-1539.
58. Rehse DH, Aye RW, Florence MG. Respiratory failure following talc pleurodesis. Am J Surg. 1999;177:437-440.
59. Genofre EH, Vargas FS, Acencio MM, et al. Talc pleurodesis: Evidence of systemic inflammatory response to small size talc particles. Respir Med. 2009;103:91-97.
60. Yildirim H, Metintas M, Ak G, et al. Predictors of talc pleurodesis outcome in patients with malignant pleural effusions. Lung Cancer. 2008;62:139-144.
61. Aydogmus U, Ozdemir S, Cansever L, et al. Bedside talc pleurodesis for malignant pleural effusion: Factors affecting success. Ann Surg Oncol. 2008.
62. Dong M, Li X, Hong LJ, et al. Advanced malignant pleural or peritoneal effusion in patients treated with recombinant adenovirus p53 injection plus cisplatin. J Int Med Res. 2008;36:1273-1278.
63. Rahman NM, Davies HE, Salzberg M, et al. Use of lipoteichoic acid-T for pleurodesis in malignant pleural effusion: A phase I toxicity and doseescalation study. Lancet Oncol. 2008;9:946-952.
64. Sioris T, Sihvo E, Salo J, et al. Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis. Eur J Surg Oncol. 2008.
65. Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest. 2006;129:362-368.
66. Warren WH, Kim AW, Liptay MJ. Identification of clinical factors predicting Pleurx catheter removal in patients treated for malignant pleural effusion. Eur J Cardiothorac Surg. 2008;33:89-94.
67. Putnam JB Jr, Light RW, Rodriguez RM, et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer. 1999;86:1992-1999.
68. Genc O, Petrou M, Ladas G, et al. The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions. Eur J Cardiothorac Surg. 2000;18:143-146.